Acura Pharmaceuticals Inc. (ACUR)

Overview

Acura Pharmaceuticals, Inc. is a prominent drug delivery company focused on the innovation, research, development, and commercialization of technologies and products aimed at enhancing the safe use of medications in the United States. Initially established as Halsey Drug Co., Inc., the company was reincorporated in 1935 and has since evolved, emphasizing the development of solutions that deter abuse of prescription drugs. Headquartered in Palatine, Illinois, Acura Pharmaceuticals continues to make significant strides in the pharmaceutical industry through its dedication to addressing critical aspects of medication safety and efficacy. Operating as a subsidiary of Abuse Deterrent Pharma, LLC, Acura has emerged as a key player, forming strategic collaboration and license agreements with notable entities such as Egalet US, Inc., Egalet Ltd., and Abuse Deterrent Pharma, LLC, to broaden the reach and impact of its innovative drug delivery technologies worldwide.

Products and Services

Acura Pharmaceuticals, Inc. has developed and commercialized several pivotal products aimed at improving patient care through innovative drug delivery and abuse-deterring technologies:

• Oxaydo Tablets: This Schedule II narcotic is specifically designed for the management of acute and chronic moderate to severe pain. By utilizing a unique formulation, Oxaydo tablets aim to deter intranasal abuse, positioning it as a critical solution in the ongoing fight against opioid misuse. Acura Pharmaceuticals has entered into collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products on a global scale.
• Nexafed Products: These comprise a line of pseudoephedrine and acetaminophen tablets, intended for use as nasal decongestants in a wide array of non-prescription and prescription cold, sinus, and allergy products. By incorporating advanced technology, Nexafed products aim to provide effective relief from nasal congestion while employing mechanisms to deter the misuse of pseudoephedrine in the illicit manufacture of methamphetamine, thereby contributing to safer communities.
• LTX-03 (In Development): This immediate-release tablet is being developed under a partnership with Abuse Deterrent Pharma, LLC. Featuring the LIMITx technology, LTX-03 is designed to mitigate the risks associated with the inadvertent overuse of acetaminophen, a common ingredient found in many over-the-counter and prescription pain relief medications. LIMITx technology offers a unique approach to abuse deterrence, potentially revolutionizing the way acetaminophen-based products are utilized, enhancing patient safety by reducing the likelihood of liver toxicity resulting from overdose.